Literature DB >> 17458568

Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance.

N Veziris1, C Martin, F Brossier, F Bonnaud, F Denis, A Aubry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17458568     DOI： 10.1007/s10096-007-0298-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   5.103


× No keyword cloud information.
  9 in total

1.  Global incidence of multidrug-resistant tuberculosis.

Authors:  Matteo Zignol; Mehran S Hosseini; Abigail Wright; Catharina Lambregts-van Weezenbeek; Paul Nunn; Catherine J Watt; Brian G Williams; Christopher Dye
Journal:  J Infect Dis       Date:  2006-07-12       Impact factor: 5.226

2.  Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2006-11-10

3.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-03-24       Impact factor: 17.586

4.  Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA.

Authors:  N Lemaitre; W Sougakoff; C Truffot-Pernot; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema.

Authors:  A M Elliott; S E Berning; M D Iseman; C A Peloquin
Journal:  Tuber Lung Dis       Date:  1995-10

7.  Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.

Authors:  I Guillemin; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

8.  [Enterobacter cloacae. In vivo emergence of a variant resistant to new beta-lactams during treatment with lamoxactam-gentamicin].

Authors:  V Jarlier; A Philippon; M H Nicolas; R Bismuth; G Paul; J Fusciardi
Journal:  Pathol Biol (Paris)       Date:  1984-05

9.  Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.

Authors:  Edward D Chan; Valerie Laurel; Matthew J Strand; Julanie F Chan; Mai-Lan N Huynh; Marian Goble; Michael D Iseman
Journal:  Am J Respir Crit Care Med       Date:  2004-01-23       Impact factor: 21.405
  9 in total
  10 in total

Review 1.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

2.  Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.

Authors:  Silke Feuerriegel; Helen S Cox; Nana Zarkua; Hamraev A Karimovich; Kai Braker; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China.

Authors:  Li-Li Zhao; Yan Chen; Hai-Can Liu; Qiang Xia; Xiao-Cui Wu; Qing Sun; Xiu-Qin Zhao; Gui-Lian Li; Zhi-Guang Liu; Kang-Lin Wan
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

4.  Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance.

Authors:  Hyun Kim; Chie Nakajima; Kazumasa Yokoyama; Zeaur Rahim; Youn Uck Kim; Hiroki Oguri; Yasuhiko Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

5.  DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Stéphanie Matrat; Florence Brossier; Sylvaine Bastian; Delphine Reitter; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Nicolas Veziris; Florence Brossier; Sylvaine Bastian; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 7.  Antituberculosis therapy for 2012 and beyond.

Authors:  Michael Lauzardo; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2012-02-15       Impact factor: 3.889

8.  Activity of carbapenems combined with clavulanate against murine tuberculosis.

Authors:  Nicolas Veziris; Chantal Truffot; Jean-Luc Mainardi; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

9.  Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase.

Authors:  Jérémie Piton; Stéphanie Petrella; Marc Delarue; Gwénaëlle André-Leroux; Vincent Jarlier; Alexandra Aubry; Claudine Mayer
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

10.  Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays.

Authors:  Danila V Zimenkov; Olga V Antonova; Alexey V Kuz'min; Yulia D Isaeva; Ludmila Y Krylova; Sergey A Popov; Alexander S Zasedatelev; Vladimir M Mikhailovich; Dmitry A Gryadunov
Journal:  BMC Infect Dis       Date:  2013-05-24       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.